Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie av Lumateperone som tilleggsterapi i behandling av pasienter med alvorlig depressiv lidelse

2. november 2026 oppdatert av: Intra-Cellular Therapies, Inc.

En randomisert, dobbeltblind, placebokontrollert multisenterstudie for å vurdere effektiviteten og sikkerheten til Lumateperone som tilleggsterapi ved behandling av pasienter med alvorlig depressiv lidelse

This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The study will be conducted in three periods:

  • Screening Period (up to 2 weeks) during which patient eligibility will be assessed.
  • Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio.
  • Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.

Studietype

Intervensjonell

Registrering (Antatt)

470

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Cherven Bryag, Bulgaria, 5980
        • Rekruttering
        • Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
      • Kardzhali, Bulgaria, 6600
        • Rekruttering
        • Medical Center Lifemed
      • Pleven, Bulgaria, 5800
        • Rekruttering
        • Medical Center Medconsult-Pleven
      • Plovdiv, Bulgaria, 4004
        • Rekruttering
        • Medical Center Mentalcare OOD
      • Sofia, Bulgaria, 1680
        • Rekruttering
        • Medical Center Intermedica, OOD
      • Sofia, Bulgaria, 1510
        • Rekruttering
        • Medical Center Hera EOOD
      • Sofia, Bulgaria, 1202
        • Rekruttering
        • MHC - Sofia, EOOD
      • Sofia, Bulgaria, 1431
        • Avsluttet
        • University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD
      • Stara Zagora, Bulgaria, 6003
        • Fullført
        • UMHAT Prof. Dr. St. Kirkovich AD
      • Varna, Bulgaria, 9020
        • Rekruttering
        • Diagnostic Consulting Center Mladost - M Varna
    • Alabama
      • Huntsville, Alabama, Forente stater, 35801
        • Rekruttering
        • University of Alabama at Birmingham
    • California
      • Pico Rivera, California, Forente stater, 90660
        • Rekruttering
        • CNRI-Los Angeles, LLC
    • Connecticut
      • Farmington, Connecticut, Forente stater, 06030
        • Rekruttering
        • University of Connecticut Health Center
    • Florida
      • Clermont, Florida, Forente stater, 34711
        • Avsluttet
        • Vertex Clinical Research
      • Hialeah, Florida, Forente stater, 33012
        • Suspendert
        • New Life Medical Research Center, Inc.
      • Miami, Florida, Forente stater, 33122
        • Rekruttering
        • Premier Clinical Research Institute
      • Miami, Florida, Forente stater, 33137
        • Rekruttering
        • Miami Jewish Health System
      • Tampa, Florida, Forente stater, 33629
        • Rekruttering
        • Interventional Psychiatry of Tampa Bay
    • Georgia
      • Atlanta, Georgia, Forente stater, 30329
        • Rekruttering
        • The Emory Clinic
      • Decatur, Georgia, Forente stater, 30030
        • Rekruttering
        • CenExeli Research LLC
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • Avsluttet
        • University of Kansas Medical Center Research Institute
      • Overland Park, Kansas, Forente stater, 66210
        • Rekruttering
        • Collective Medical Research
    • Massachusetts
      • Methuen, Massachusetts, Forente stater, 01844
        • Avsluttet
        • ActivMed Practices and Research
    • Missouri
      • O'Fallon, Missouri, Forente stater, 63368
        • Rekruttering
        • Psychiatric Care and Research Center (PCRC)
    • New Jersey
      • Toms River, New Jersey, Forente stater, 08755
        • Rekruttering
        • Bio Behavioral Health
    • New York
      • Brooklyn, New York, Forente stater, 11235
        • Rekruttering
        • SPRI Clinical Trials, LLC
      • New York, New York, Forente stater, 10036
        • Rekruttering
        • Manhattan Behavioral Medicine
    • Ohio
      • Avon Lake, Ohio, Forente stater, 44012
        • Rekruttering
        • Quest Therapeutics of Avon Lake
      • Cincinnati, Ohio, Forente stater, 45219
        • Rekruttering
        • University of Cincinnati Medical Center
      • Columbus, Ohio, Forente stater, 43210
        • Rekruttering
        • The Ohio State University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • University of Pennsylvania - Perelman School of Medicine
    • Texas
      • Houston, Texas, Forente stater, 77081
        • Rekruttering
        • DM Clinical Research
      • Mansfield, Texas, Forente stater, 76063
        • Fullført
        • Hawkins Psychiatry, PC
      • Richardson, Texas, Forente stater, 75080
        • Rekruttering
        • Pillar Clinical Research, LLC
    • Washington
      • Bellevue, Washington, Forente stater, 98007
        • Rekruttering
        • Northwest Clinical Research Center
      • Douai, Frankrike, 59500
        • Rekruttering
        • Cabinet Medical des Drs Prizac-Desbonnet Scottez
      • Nantes, Frankrike, 44093
        • Rekruttering
        • CHU de Nantes hotel Dieu
      • Nîmes, Frankrike, 30029
        • Rekruttering
        • Hopital Caremeau
      • Paris, Frankrike, 75012
        • Rekruttering
        • Groupe Hospitalier Pitie-Salpetriere
      • Poitiers, Frankrike, 86021
        • Rekruttering
        • CH Henri Laborit
      • Ahmedabad, India, 380008
        • Suspendert
        • Ratandeep Surgical Hospital And Endoscopy Clinic
      • Ahmedabad, India, 380009
        • Suspendert
        • Sushrusha Navneet Memorial Hospital
      • Ajmer, India, 305001
        • Suspendert
        • J L N Medical College and Attached Hospitals
      • Bikaner, India, 334001
        • Rekruttering
        • S P Medical College And Associated Group of Hospitals
      • Bārāmati, India, 413102
        • Rekruttering
        • Baramati Hospital
      • Chandigarh, India, 160012
        • Rekruttering
        • Post Graduate Institute of Medical Education And Research PGIMER
      • Guwahati, India, 781032
        • Fullført
        • Gauhati Medical College and Hospital
      • Kolhāpur, India, 416001
        • Rekruttering
        • Swastik Hospital
      • Nagpur, India, 440001
        • Rekruttering
        • KIMS-Kingsway Hospitals
      • Palsāna, India, 394315
        • Rekruttering
        • Divyam Hospital
      • Pune, India, 411011
        • Rekruttering
        • Shree Samarth Hospital
      • Rajkot, India, 360001
        • Fullført
        • Nagecha Hospital
      • Wardha, India, 442004
        • Suspendert
        • Acharya vinoba bhave rural hospital
      • Kaunas, Litauen, LT-44279
        • Fullført
        • Romuvos Klinika, JSC
      • Ziegzdriai, Litauen, 53136
        • Fullført
        • Kaunas Hospital of Lithuanian University of Health Sciences Psychiatric Clinic Mariu division
      • Belgrade, Serbia, 11000
        • Rekruttering
        • University Clinical Center of Serbia
      • Belgrade, Serbia, 11000
        • Rekruttering
        • Institute of Mental Health Serbia
      • Belgrade, Serbia, 11000
        • Rekruttering
        • Clinical Center Dr Dragisa Misovic Dedinje
      • Kovin, Serbia, 26220
        • Rekruttering
        • Special Hospital for Psychiatric Diseases Kovin
      • Kragujevac, Serbia, 34000
        • Rekruttering
        • University Clinical Center Kragujevac
      • Kragujevac, Serbia, 34000
        • Rekruttering
        • University Clinical Center Kragujevac 1
      • Niš, Serbia, 18000
        • Rekruttering
        • University Clinical Center NIS 1
      • Niš, Serbia, 18000
        • Rekruttering
        • University Clinical Center NIS
      • Novi Kneževac, Serbia, 23330
        • Rekruttering
        • Special Hospital for Psychiatric Diseases Sveti Vracevi
      • Barcelona, Spania, 08036
        • Rekruttering
        • Hosp. Clinic de Barcelona
      • Barcelona, Spania, 08035
        • Rekruttering
        • Hosp Univ Vall D Hebron
      • Madrid, Spania, 28034
        • Fullført
        • Hosp. Univ. Ramon Y Cajal
      • Sabadell, Spania, 08208
        • Rekruttering
        • Hosp.Univ.Parc Tauli
      • Zamora, Spania, 49021
        • Rekruttering
        • Hosp. Prov. de Zamora

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female patients between the ages of 18 and 65 years, inclusive;

  2. Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria:

    1. The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening;
    2. Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
    3. Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
    4. Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;
    5. Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
  3. Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:

    1. citalopram/escitalopram
    2. fluoxetine
    3. paroxetine
    4. sertraline
    5. duloxetine
    6. levomilnacipran/milnacipran (if locally approved for MDD)
    7. venlafaxine/desvenlafaxine
    8. bupropion
    9. vilazodone
    10. vortioxetine

Exclusion Criteria:

  1. Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:

    1. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
    2. Bipolar Disorder;
  2. Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:

    1. Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment;
    2. Eating disorder;
    3. Substance use disorders (excluding nicotine);
    4. Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
    5. Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
  3. The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;

  4. The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;

  5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:

    1. At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
    2. At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
    3. At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
    4. The patient is considered to be in imminent danger to him/herself or others.
  6. The patient has a first MDE at age 60 years or older.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Matching capsules administered orally, once daily

Eksperimentell: Lumateperon 42 mg

Lumateperone 42 mg capsules administered orally, once daily

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Montgomery-Asberg Depression Rating Scale
Tidsramme: Day 43

The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

Day 43

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Clinical Global Impression Scale-Severity
Tidsramme: Day 43

The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Day 43

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Intra-Cellular Therapies, Inc. Clinical Trial, Intra-Cellular Therapies, Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. mai 2023

Primær fullføring (Antatt)

5. april 2027

Studiet fullført (Antatt)

5. april 2027

Datoer for studieregistrering

Først innsendt

28. april 2023

Først innsendt som oppfylte QC-kriteriene

29. april 2023

Først lagt ut (Faktiske)

9. mai 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ITI-007-505
  • ITI-007-505 (Annen identifikator: Janssen Research & Development, LLC)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .